Status:
COMPLETED
Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs
Lead Sponsor:
Jyoti Clinical and Pathological Laboratory
Conditions:
Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents
Eligibility:
All Genders
30-60 years
Phase:
PHASE2
Brief Summary
To determine the safety and efficacy of an Ayurvedic formulation, Mersina in type 2 diabetic patients with secondary failure to oral hypoglycemic agents, a randomized double blind, single centre, stud...
Eligibility Criteria
Inclusion
- Secondary failure to Oral Hypoglycemic Agents was diagnosed if the patient had HbA1c levels \> 8.5% even after supplementation of maximal dose of a combination of a sulphonylurea (15 mg glybenclamide or 160 mg gliclazide or 15 mg glipizide) and metformin 1500 mg/day.
Exclusion
- Patients with ketosis, diabetes related complications, hepatic or renal disease, pancreatitis, cardiac problems, uncontrolled hypertension, malnutrition and severe immune deficiency
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00940251
Start Date
September 1 2008
End Date
November 1 2008
Last Update
July 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jyoti Clinical and Pathological Laboratory
Shirpur, Maharashtra, India, 425 405